{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T05:45:19Z","timestamp":1775281519262,"version":"3.50.1"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.intimp.2023.109950","type":"journal-article","created":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T01:06:02Z","timestamp":1677719162000},"page":"109950","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["A pilot trial of Thymalfasin (Ta1) to prevent covid-19 infection and morbidities in renal dialysis patients: Preliminary report"],"prefix":"10.1016","volume":"117","author":[{"given":"Cynthia W.","family":"Tuthill","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Awad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Parrigon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William B.","family":"Ershler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2023.109950_b0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2020.101205","article-title":"Aging in COVID-19: Vulnerabiilty, immunity, and intervention","volume":"65","author":"Chen","year":"2021","journal-title":"Ageing Res. Rev."},{"issue":"6","key":"10.1016\/j.intimp.2023.109950_b0010","first-page":"332","article-title":"Clinical investigation of outbreak of nosocomial severe acute respiratory syndrome","volume":"15","author":"Gao","year":"2003","journal-title":"Zhongguo Wei Zhong Bing Ji Jiu Yi Xue"},{"issue":"1","key":"10.1016\/j.intimp.2023.109950_b0015","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.transproceed.2006.10.005","article-title":"Immunoregulation of thymosin alpha 1 treatment of cytomegalovirus infection accompanied with acute respiratory distress syndrome after renal transplantation","volume":"39","author":"Ji","year":"2007","journal-title":"Transplant Proc."},{"issue":"4","key":"10.1016\/j.intimp.2023.109950_b0020","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3109\/08923973.2015.1069837","article-title":"Thymosin alpha1 plus routine treatment inhibit inflammatory reaction and improve the quality of life in AECOPD patients","volume":"37","author":"Jia","year":"2015","journal-title":"Immunopharmacol. Immunotoxicol."},{"issue":"8","key":"10.1016\/j.intimp.2023.109950_b0025","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s00262-015-1708-2","article-title":"Impact of the immunomodulating peptide thymosin alpha 1 on multiple myeloma and immune recovery after hematopoietic stem cell transplantation","volume":"64","author":"Binsfeld","year":"2015","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.intimp.2023.109950_b0030","article-title":"Thymosin alpha 1 reduces the mortality of severe COVID-19 by restoration of lymphocytopenia and reversion of exhausted T cell","author":"Liu","year":"2020","journal-title":"Clin. Inf. Dis."},{"issue":"9","key":"10.1016\/j.intimp.2023.109950_b0035","first-page":"913","article-title":"A double-blind multicenter two-arm randomized placebo-controlled phase-III clinical study to evaluate the effectiveness and safety of thymosin alpha 1 as an add-on treatment to existing standard of care treatemnt in moderate-to-severe COVID-19 patients","volume":"26","author":"Shetty","year":"2020","journal-title":"Indian J. Crit. Care Med."},{"issue":"2","key":"10.1016\/j.intimp.2023.109950_b0040","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1093\/infdis\/jiac362","article-title":"A pilot trial of thymalfastin (thymosin alpha 1) to treat hospitalized patients with hypoxemia and lymphocytopenia due to coronavirus disease 2019 infection","volume":"227","author":"Shehadeh","year":"2023","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.intimp.2023.109950_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.109584","article-title":"Thymosin alpha 1 use in adult COVID-19 patients: a systematic review and meta-analysis on clinical outcomes","volume":"114","author":"Shang","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2023.109950_b0050","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ijid.2014.12.032","article-title":"Thymosin alpha1 based immunomodulatory therapy for sepsis: a systematic review and meta-analysis","volume":"33","author":"Li","year":"2015","journal-title":"Int. J. Infect. Dis."},{"issue":"sup1","key":"10.1016\/j.intimp.2023.109950_b0055","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1080\/14712598.2018.1484104","article-title":"Thymosin alpha 1 treatment for patients with sepsis","volume":"18","author":"Pei","year":"2018","journal-title":"Expert Opin. Biol. Ther."},{"issue":"1","key":"10.1016\/j.intimp.2023.109950_b0060","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/jvh.12807","article-title":"Immunotherapy for hepatitis B in the direct acting antiviral era: Reevaluating the thymosin alpha1 efficacy trials in the light of a combination therapy approach","volume":"25","author":"Naylor","year":"2018","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.intimp.2023.109950_b0065","doi-asserted-by":"crossref","first-page":"873","DOI":"10.3389\/fonc.2019.00873","article-title":"A Reappraisal of Thymosin Alpha1 in Cancer Therapy","volume":"9","author":"Costantini","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.intimp.2023.109950_b0070","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.vaccine.2011.12.014","article-title":"\u201cThymosin alpha 1 (ZADAXIN) enhances the immunogenicity of an adjuvanted pandemic H1N1v influenza vaccine (Focetria) in hemodialyzed patients: a pilot study","volume":"30","author":"Carraro","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.intimp.2023.109950_b0075","first-page":"188A","article-title":"Augmentation of influenza antibody levels and reduction in attack rates in elderly subjects by thymosin alpha 1","volume":"29","author":"McConnell","year":"1989","journal-title":"The Gerentologist."},{"key":"10.1016\/j.intimp.2023.109950_b0080","article-title":"Effect of thymosin alpha 1 on heptavax-B vaccination among hemodialysis patients","volume":"217","author":"Shen","year":"1987","journal-title":"Kidney Int."},{"key":"10.1016\/j.intimp.2023.109950_b0085","first-page":"1120","article-title":"Effects of thymosin alpha 1 on peripheral T-cell and Heptavax-B vaccination in previously non-responsive hemodialysis patients","volume":"7","author":"Shen","year":"1987","journal-title":"Hepatology."},{"key":"10.1016\/j.intimp.2023.109950_b0090","series-title":"Biomedical Advances in Aging","first-page":"523","article-title":"Age-dependent enhancement of influenza vaccine responses by thymosin in chronic hemodialysis patients","author":"Shen","year":"1990"},{"key":"10.1016\/j.intimp.2023.109950_b0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1532-5415.1989.tb01561.x","article-title":"Augmentation of influenza antibody response in elderly men by thymosin alpha one. A double-blind placebo-controlled clinical study","volume":"37","author":"Gravenstein","year":"1989","journal-title":"J. Am. Geriatr. Soc."},{"key":"10.1016\/j.intimp.2023.109950_b0100","first-page":"150A","article-title":"Anti-influenza antibody response: augmentation in elderly non-responders by thymosin alpha 1","volume":"26","author":"Gravenstein","year":"1986","journal-title":"Gerontologist."},{"issue":"7","key":"10.1016\/j.intimp.2023.109950_b0105","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1182\/blood-2006-02-004762","article-title":"Thymosin alpha1 activates dendritic cell tryptophan catabolism and establishes a regulatory environment for balance of inflammation and tolerance","volume":"108","author":"Romani","year":"2006","journal-title":"Blood."},{"key":"10.1016\/j.intimp.2023.109950_b0110","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1196\/annals.1415.002","article-title":"Thymsoin alpha 1: an endogenous regulator of inflammation, immunity, and tolerance","volume":"1112","author":"Romani","year":"2007","journal-title":"Ann. N.Y. Acad. Sci."},{"key":"10.1016\/j.intimp.2023.109950_b0115","first-page":"5","article-title":"Jack of all trades: thymosin alpha 1 and its pleiotropy","volume":"1269\u20131270","author":"Romani","year":"2012","journal-title":"Ann. N.Y. Acad. Sci."},{"key":"10.1016\/j.intimp.2023.109950_b0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1749-6632.2010.05465.x","article-title":"Thymosin alpha 1: the regulator of regulators?","volume":"1194","author":"Pierluigi","year":"2010","journal-title":"Ann. N.Y. Acad. Sci."},{"issue":"5","key":"10.1016\/j.intimp.2023.109950_b0125","doi-asserted-by":"crossref","first-page":"854","DOI":"10.2215\/CJN.05760516","article-title":"Serious Illness Conversations in ESRD","volume":"12","author":"Mandel","year":"2017","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.intimp.2023.109950_b0130","doi-asserted-by":"crossref","unstructured":"S.Y. Shen, et al., eds. Age-dependent enhancement of influenza vaccine response by thymosin in chronic hemodialysis patients. Biomedical Advances in Aging \u201888, ed. A.L. Goldstein. 1990, Plenum Medical Publishers. 523-530.","DOI":"10.1007\/978-1-4613-0513-2_52"},{"key":"10.1016\/j.intimp.2023.109950_b0135","unstructured":"United States Renal Data System. 2020 USRDS Annual Data Report: Epidemiology of Kidney Disease in the United States. National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, US Department of Health and Human Services."},{"key":"10.1016\/j.intimp.2023.109950_b0140","doi-asserted-by":"crossref","DOI":"10.1681\/ASN.2021050611","article-title":"Antibody response to COVID-19 vaccination in patients receiving dialysis","author":"Anand","year":"2021","journal-title":"J. Amer. Soc. Nephrology"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923002709?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923002709?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:57:27Z","timestamp":1761587847000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576923002709"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":28,"alternative-id":["S1567576923002709"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2023.109950","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A pilot trial of Thymalfasin (Ta1) to prevent covid-19 infection and morbidities in renal dialysis patients: Preliminary report","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2023.109950","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109950"}}